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Abstract
The discovery of a novel serum autoantibody (termed NMO-IgG or AQP4-Ab) in a subset of patients in 2004 has
revived interest in neuromyelitis optica (NMO). While the history of classical multiple sclerosis has been extensively
studied, only little is known about the history of NMO. In the present article, we provide a comprehensive review of
the early history of this rare but intriguing syndrome. We trace the origins of the concept of NMO in the 19th
century medical literature and follow its evolution throughout the 20th and into the 21st century. Finally, we
discuss recent proposals to revise the concept of NMO and explain why there is indeed a need for a more
systematic and descriptive nomenclature.
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Introduction
Neuromyelitis optica (NMO) is a rare condition, charac-
terized by myelitis and optic neuritis, which shares a
number of clinical and radiological features with mul-
tiple sclerosis (MS) [1-3]. The groundbreaking discovery
of a novel, pathogenic autoantibody (termed NMO-IgG
or AQP4-Ab) in a subset of patients by Dr Lennon and
colleagues in 2004 [4,5] has led to a tremendous increase
in interest in NMO. NMO-IgG/AQP4 antibody-positive
NMO is now considered a disease entity in its own right
rather than a subtype of MS.
While the history of classical MS has been studied ex-
tensively, only little is known about the history of NMO.
In the present article, we comprehensively review the
early history of NMO. We trace the first accounts of this
peculiar term in the 19th century French-, English-, and
German-language literature and follow its definition’s
meandering evolution throughout the 20th and into the
21st century. Finally, we will discuss recent proposals to
re-define or substitute the term and explain why there
is indeed a need for a more systematic and descriptive
nomenclature.
Eugène Devic and Fernand Gault
‘Neuromyelitis optica acuta’ and the more rarely used
English equivalent ‘acute optic neuromyelitis’ are both
translations of the French term ‘neuro-myélite optique
aiguë’, which was first used by Eugène Devic (1858–1930)
in a paper communicated on the occasion of the Congrès
Français de Médecine in Lyon in 1894 (Figures 1 and 2).
Devic intended the term to denote a novel syndrome char-
acterized by acute myelitis and optic neuritis: ‘Ces seize
cas de myélite aiguë accompagnés de névrite optique sont
suffisants pour légitimer la création d’un type clinique, ou
plutôt d’un syndrome auquel on pourrait donner le nom
de neuro-myélite optique’ [6].
The same year, Devic’s student Fernand Gault (1873–
1936) published his doctoral thesis, entitled De la neuro-
myélite optique aiguë (Figure 3), which consisted of a
review of the previous medical literature and a clinico-
pathological analysis of Devic’s case [7]. (The fact that
the congress proceedings with Devic’s abstract appeared
only in 1895, i.e. after Gault’s thesis, has given rise to
some confusion in the literature. However, Devic gave
his presentation on Friday, 26th October 1894; by con-
trast, Gault’s thesis was printed only in November 1894
according to the imprint, and its dedication is dated ‘20
novembre 1894’.)
We will never know with absolute certainty whether it
was Devic or Gault who originally invented the term;
however, the following lines from Gault’s thesis strongly
suggest it was indeed Devic: ‘Bien que l’axiome « Il n’y a
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pas de maladies, il n’y a que des malades » soit toujours
vrai, il est certain cependant que, quand on parvient à
réunir en un syndrome un ensemble constant de symp-
tômes, il est certain, dis-je, que l’on peut proposer un
nom servant à désigner le cas type, et sur les conseils de
M. le Dr Devic, je propose celui de neuro-myélite dif-
fuse, aiguë’ [7].
There is some evidence that the term ‘neuro-myélite’
was chosen by Devic and Gault in analogy with ‘neuro-
cérébrite’, a term associated with the name of August
Pierret. Pierret, a pupil of Charcot and at that time pro-
fessor at the Clinique des maladies mentales at Lyon,
was president of the examination board committee re-
sponsible for Gault’s thesis. Moreover, Gault’s thesis was
dedicated to Pierret, and its very last sentence reads: ‘Ce
syndrome relève probablement dans un certain nombre
de cas de l’infection. C’est un exemple nouveau d’un
processus infectieux, frappant à la fois deux points
éloignés du système nerveux sans qu’il y ait de lésions
anatomiques quelconques reliant ces deux foyers. A ce
titre, ce syndrome mérite d’être rapproché de la neuro-
cérébrite de M. le professeur Pierret’ [7].
(In 1935, the Berlin neurologist Erwin Stengel would
make an attempt to resuscitate Pierret’s term in a paper
on a series of patients with neuritis cranialis and accom-
panying brainstem encephalitis, in which he proposed to
refer to such cases by the term ‘neuro-encephalitis’.
Interestingly, one of his patients had optic neuritis, and
Stengel wrote: ‘Der Fall, bei dem auch eine Neuritis
optica bestand, könnte in Analogie zur Bezeichnung
Neuromyelitis optica als Neuroencephalitis optica [italics
ours] bezeichnet werden’ [8]. Recent studies have shown
that brainstem involvement is quite common in patients
with AQP4 autoimmunity, and cases of AQP4 antibody-
positive ‘neuroencephalitis optica’ without concomitant
myelitis indeed occur [1,9]. —A very early account of
Figure 1 Eugène Devic (1858–1930).
Figure 2 Heading and first paragraph of Eugène Devic’s
famous abstract for the Congrès Français de Médecine in Lyon
in 1894.
Figure 3 Title page of Fernand Gault’s doctoral thesis De la
neuromyélite optique aiguë (Lyon, November 1894).
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possible ‘neuroencephalitis optica’ is to be found in the in
the second, enlarged edition (1829) of John Abercrombie’s
(1780–1844) Pathological and Practical Researches on
Diseases of the Brain and Spinal Cord, a case of intrac-
table vomiting, relapsing visual loss, and spinal pain
[10,11]; intractable vomiting and hiccups are typical mani-
festations of medulla oblongata involvement in aquaporin-
4 antibody-positive NMO and often herald the onset of
myelitis [12,13]).
While several articles on Devic’s life have been published,
only little is known about Gault’s biography. According to
Politzer’s monumental Geschichte der Ohrenheilkunde,
Gault worked as an army doctor following his graduation
from the Lyon faculty in 1894, but soon became professor
of otorhinolaryngology at the Medical School in Dijon (in
1905) and head of the ENT department there in 1911 [14].
We traced more than 20 publications authored or co-
authored by Gault; however most of them were dedicated
to ENT topics. It seems that Gault never again published
on NMO. He died in 1936, just six years after Devic.
NMO before Devic and Gault
As recently shown by us [10,15-17], Devic and Gault in
their reviews overlooked some early cases of possible
NMO, probably owing to the restricted bibliographic
resources of the time (both Devic’s and Gault’s lists of
references were mainly based on that of an earlier Ger-
man review by the Dresden-based ophthalmologist Fritz
Schanz [18], as conceded by Devic in reference [19]). In
1844, i.e. 26 years prior to the first case referenced
by Devic and Gault, the Genoese physician Giovanni
Battista Pescetto (1806–1884) had reported on a 42-year-
old man who simultaneously developed acute amaurosis
and cervical myelitis, with complete recovery following
extensive bloodletting [10]; in 1850, the British physician
Christopher Mercer Durrant (1814–1901) had described
a case of tetraparesis and (partly reversible) bilateral am-
aurosis in the precursor of the British Medical Journal
[20]; and in 1862 the British neuroanatomist, neuropa-
thologist, and neurologist Jacob Augustus Lockhart
Clarke (1817–1880), known to many as the eponym of
Clarke’s column, the posterior thoracic nucleus, had
reported the case of a 17-year-old girl with bilateral
optic neuritis and longitudinally extensive transverse
myelitis in The Lancet [15]. Finally, a report by Antoine
Portal (1742–1832), first physician to Louis XVIII and
founding and lifelong president of the Académie Nationale
de Médecine, deserves to be mentioned here: it represents
the first account of visual loss in a patient with spinal cord
inflammation but no brain pathology in the Western lit-
erature known so far [16]. However, none of these previ-
ous authors had ever used the term ‘neuromyelitis optica’
or a similar one.
Peppo Acchioté
In 1907, Peppo Acchioté (1870–1916; the original Turkish
spelling is Pe(p)po Akşiyote or Akşiyoti (Kirbaş, 2003)), a
physician from Constantinople, ‘spécialiste pour les mala-
dies nerveuses et sur l’électrothérapie’ [21], proposed for
the first time - in a paper communicated by no less a fi-
gure than Joseph Babinski (1857–1932) on 4th July 1907
on the occasion of a session of the Société de Neurologie
de Paris - to make Devic the eponym of NMO: ‘L’associa-
tion de névrite optique avec une myélite diffuse constitue
l’affection denommée par M. Devic, de Lyon, neuromyélite
optique aiguë et qu’il serait plus juste, à mon avis, de de-
signer sous le nom de maladie de Devic’ [22].
In this paper, Acchioté also reported on a case of his
own, a 25-year-old woman with bilateral optic neuritis,
paraparesis, and sensory and sphincter disturbances.
In choosing the term ‘maladie’, Acchioté deviated from
Devic’s original definition of NMO as a ‘syndrome’ or ‘type
clinique’ [6]. This deviation has consequences to our day,
as we will discuss below. It should not go unmentioned,
however, that Acchioté’s choice of the word ‘maladie’ has
in fact some foundation in Gault’s thesis. While Devic ori-
ginally described NMO as a ‘syndrome’ or ‘type clinique’,
Gault was more ambiguous. While he defined ‘NMO’, fol-
lowing Devic, as a ‘syndrome’ or ‘complexus symptoma-
tique’ in the final conclusion of his thesis - characterized
by bilateral optic neuritis (simultaneously or alternately),
usually resulting in complete yet mostly transient amau-
rosis (with possible full functional recovery), and diffuse
or localized acute myelitis, with the latter mostly following
the optic nerve affliction - he wrote in the introduction to
his thesis: ‘Le syndrome dont nous voulons parler consti-
tue cependant une entité morbide [italics ours] bien dis-
tincte et ayant droit de cité dans le cadre nosologique’ [7].
Elsewhere in his paper, Acchioté used the more neutral
French term ‘affection’ [22].
Little is known about Acchioté’s life. According to
Dursun Kirbaş’s History of Turkish Neurology (Türkiye
Nöroloji Tarihçesi), Acchioté (Figure 4) studied in Paris
[23]. We could identify a proceeding that lists him as a
visiting physician at the Service des enfants idiots, épilep-
tiques et arriérés at the Bicêtre in 1903 [21]. Later, he
was a member of the teaching staff at the Istanbul Civi-
lian Medical School and, at least from 1910 on, assistant
professor at the Neurology Department of the Haydar-
paşa Medical Faculty, as deputy to Raşit Tahsin, a pupil
of Kraepelin, Binswanger, and Mendel, and one of the
pioneers in neurology in Turkey [24].
Given that numerous case reports and at least two
reviews [11,19] on the association of myelitis and amau-
rosis were published prior to Devic and Gault, Acchioté’s
proposal may be considered another example of what
Robert Merton (rather playfully) once called the palimp-
sestic (or anatopic) syndrome, which is not so rare a
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phenomenon in the history of medicine: ‘the altogether
innocent transmitter becomes identified as the origin-
ator of the idea when his merit lies only in having kept it
alive (. . .) or perhaps in having put it to new or instruct-
ive use’ [20]. That said, not mentioning Devic and
Gault’s unique contribution would mean committing
what Merton called the ‘sin of adumbrationism’ [20]:
While others had in fact reported on NMO before, it
was they who gave it a name - and ‘[w]hat is a disease
before it gets a name?’ (T. Jock Murray, Multiple Sclerosis:
The History of a Disease, New York, 2005).
Acchioté’s proposal was soon made known to a broader
audience by the reprinting of his paper in the Revue neu-
rologique [25] and by a short summary that appeared later
the same month in the Annales d’oculistique [26].
Some authors have proposed to revise Acchioté’s epo-
nymous designation to acknowledge also Gault’s impor-
tant contribution to the history of NMO [27,28].
‘NMO’: early accounts in the non-French literature
Devic never used the neoclassical adaption ‘neuromyelitis
optica’ widely preferred today. The earliest use of that ver-
sion we could trace is found in a 1904 German-language
review by the Austrian psychiatrist Erwin Stransky [29], a
pioneer in research on schizophrenia (for a brief sketch of
Stransky’s disturbing biography see ref. [30]). In this arti-
cle, Stransky summarized and discussed a report by the
French pathologist and neurologist Édouard Brissaud, a
pupil of Charcot and Lasègue, about a 16-year-old boy
with NMO, which had appeared in the Revue Neurologi-
que earlier the same year [31].
The first two uses of the English-language term ‘acute
optic neuromyelitis’, and at the same time the first ac-
count of a variant of ‘NMO’ in any language other than
French we could find, were in a September 1903 issue of
the British Medical Journal [32], in an anonymous re-
view of Weill and Gallavardin’s case in the Lyon Medi-
cale [33] (an exact reprint of that review appeared in the
December 1903 issue of The Ophthalmoscope [34]), and
in a short review by Hugh T. Patrick, Professor of Neur-
ology at Northwestern University, of the same French
report in the 10th volume of the 1904 edition of the
Practical Medicine Series of Year Books, which appeared
the same month [35]. Also in 1904, Gowers’ authori-
tative textbook on the ophthalmoscopic signs of neu-
rological diseases appeared in a revised edition [36].
However, Gowers, who was well aware of the still rela-
tively rare reports on the coincidence of optic neuritis
and acute myelitis and who had taken part in the early
discussions regarding the pathogenic relationship bet-
ween these two afflictions, did not adopt the term ‘neu-
romyelitis’ in this or, to the best of our knowledge, in
any other of his writings.
While most later authors writing in English and German
would use the neoclassical term (rare exceptions are Perrit
[37] and Vernant et al. [38]), local spellings (‘neuromielite
ottica’ and ‘neuromielitis óptica’, respectively) were used in
some of the early Italian- [39,40] and Spanish-language
[41] publications on NMO, and Devic’s original version
has remained prevalent in the French-language literature
to this day.
Alternative denominations
In his communication, Devic proposed ‘neuroptico-
myélite’ as an alternative denomination. However, this
term has not been widely adopted by neurologists (rare
exceptions are to be found in Bouchut and Dechaume
[42], and Euzière and Bremond [43]). In his thesis, Gault
once used the term ‘neuro-myélite diffuse aigüe’; which
refers to ‘myélite diffuse’ but, surprisingly, makes no
mention of the optic nerve. Other rare variants used in a
handful of publications include ‘neuro-optic myelitis’
[44], ‘neurópticomielitis aguda’ [45], ‘neuropticomielitis’
[41], ‘opthalmoneuromyélite’ [46-48], ‘oftalmomielitis’
[41], and ‘mielitis oftálmica’ [41].
Etymology
Evidently, ‘neuromyelitis optica’ and ‘neuropticomyelitis’ are
artificial composites of myelitis, i.e. inflammation of the
spinal cord, and ‘neuritis (cranialis) optica’, a problematic
(strictly speaking, a neuritis cannot be ‘optical’; however, as
a sort of constructio ad sensum, some may nevertheless
consider that expression acceptable) and, accordingly, not
Figure 4 Peppo Acchioté (1870–1916).
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widely used (a famous exception is Wilhelm Erb’s early de-
scription of NMO, which was entitled Über das Zusam-
menvorkommen von Neuritis optica und Myelitis subacuta
[49]; see also Noyes [50]) alternative to the more correct
term ‘neuritis nervi optici’, i.e. inflammation of the optic
nerve. Etymologically, they are combining forms of the An-
cient Greek words νεῦρον, i.e. nerve, sinew or tendon, and
μυελός, i.e. marrow (probably a derivative of μυών, muscle),
the post-classical Latin word optica, and the suffix -itis,
which was already used in Greek to indicate disease
(though not necessarily inflammation). As ‘neuropticomye-
litis’ is a Greek-Latin hybrid and because ‘optic myelitis’
does not, strictly speaking, make much sense, purists might
regard these terms as linguistic barbarism [51]. However,
such classical compounds are common in medical termin-
ology with its strong need for classification and, in conse-
quence, distinguishing denominations; accordingly, the
term was widely accepted and has survived to our days.
Previous usage of the term ‘neuromyelitis’: Dunglison and
Hildenbrand
It is little known that compounds of νεῦρον and μυελός
had been in existence before Devic’s time. The 1836 edi-
tion of the prestigious Dictionnaire de l’Académie Fran-
çaise defined ‘névromyélite’ as ‘inflammation de la
moelle épinière’ and, thus, as a synonym of ‘myélite’.
However, we did not find evidence in the medical litera-
ture of the time that the term thus defined was widely
used; instead, it seems to have led a lonely existence in
that dictionary as a hapax legomenon. The same holds
true for the (etymologically corrupt) definition of
‘neuro-myelitis’ as inflammation of the vertebra in an
1875 Italian dictionary [52]. However, the etymological
explanations given above indicate that the term ‘neuro-
myelitis’ may also be used (and perhaps with more justi-
fication from a linguistic point of view) to refer to
inflammation of the medulla nervorum. In fact, the word
was defined in Robley Dunglison’s (then widely used)
19th century Medical Lexicon exactly in this sense:
‘NEUROMYELI’TIS, from νευρον, “a nerve”, μυελοs,
“marrow”, and itis, denoting inflammation. Inflammation
of the medullary matter of the nerves’. This definition is
first documented in the 1848 edition of that early Dic-
tionary of Medical Science (as its subtitle reads), and we
found it in a number of (later) German dictionaries as
well (cf. Ernst Gabler, Lateinisch-deutsches Wörterbuch
für Medicin und Naturwissenschaften, Berlin, 1857:
‘Neuromyelitis, die Entzündung des Nervenmarks. Neu-
romyelos, das Nervenmark’, Wilhelm Probstmayr, Etymo-
logisches Wörterbuch der Veterinär-Medicin und ihrer
Hilfswissenschaften, Munich, 1863: ‘Neuromyelitis (. . .),
die Entzündung des Nervenmarks = Inflammatio medul-
lae nerveae’).
One of the few accounts of the term ‘neuromyelitis’ as
defined by Dunglison (or, more exactly, ‘nevromyelitis’) -
and at the same time the earliest one we are aware of - in
the medical literature is to be found in the third volume of
Johann Valentin Hildenbrand’s famous Institutiones prac-
tico-medicae (published posthumously by his son in 1822)
[53] (Figure 5). Hildenbrand (1763–1818) used the term
to distinguish inflammation of the pulpa nervorum from
that of the vagina nervorum, to which he referred as ‘nev-
rilemmatitis’: ‘Longe obscurius incedit phlogosis pulpae
nervosae (Nevromyelitis); confunduntur enim tunc phae-
nomena, quae inflammationem in genere denotare solent,
plurimum imperfecte evoluta, cum symptomatibus nervo-
sis hyperaesthesiam, vel spasmum indicantibus’ [53]. An-
other early instance is to be found in Ernst von Grossi’s
Familiarum morborum humanorum expositio: ‘inflamma-
tio medullae nervae diversae seu neuromyelitis’ [54].
The presence of a vagina nervorum as opposed to the
medulla was already recognized by earlier authors (who,
Figure 5 Title page of the third volume of Johann Valentin
Hildenbrand’s Institutiones practico-medicae (Vienna, 1822;
published posthumously).
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though, did not use the term ‘nevromyelitis’) as reviewed
by Georg Prohaschka in his 1779 De Structura Nervorum:
Tractatus Anatomicus Tabulis Aeneis Illustratus (see Section
I, caput V). However, these early authors (as well as some
of the later ones, e.g. Joseph Hyrtl, Lehrbuch der Anatomie
des Menschen, 1857: ‘Das Neurilemm enthält die Ernäh-
rungsgefässe des Nerven, und führt sie seinen Bünde-
labtheilungen zu’) rather had in mind the connective
tissue (epi-, peri-, and endoneurium) investing the nerves,
nerve fascicles, and nerve fibres. It was not until 1838/39
that Schwann identified the cell type that commemorates
his name, and Ranvier would still bemoan the lack of
knowledge and confusion in the nomenclature regarding
the nerve sheaths in 1872.
This distinction was soon criticized by Pierre Adolphe
Piorry (1794–1879), one of the fathers of percussion and in-
ventor of the plessimeter, as artificial and lacking experi-
mental evidence: ‘A plus forte raison en est-il ainsi du
diagnostic qu’on a voulu établir entre la névromyélite et la
névrilemmite [italics ours]. (. . .) [I]l aurait bien mieux valu
la répéter, et, jusqu’à temps qu’on fasse voir le névrilemme
d’un filet nerveux enflammé indépendamment de sa pulpe,
et vice versa, il sera permis de ne pas croire à ces distinction
subtiles qui, à coup sûr, ne sont pas nées d’observations
cliniques rigoureuses’ [55]. In 1850, Piorry would repeat his
harsh criticism, arguing that the difference would be of little
therapeutic consequence: ‘C’est une chose curieuse que de
voir l’assurance avec la quelle Boisseau et d’autres patholo-
gistes établissent des caractères distinctifs de la névrilèmite
et de la névrite qu’ils appellent aussi névromyélite. (. . .) au
point de vue pratique a bien peu d’importance. Nous ne
voyons pas en effet, quelles seraient les différences à établir
sous le rapport du traitement entre la phlegmasie d’un nerf
et celle de son enveloppe’ [56].
Piorry’s article was published in 1833 in his Clinique méd-
icale de l’hôpital de la Pitié et de l’hospice de la Salpétrière
[55] and reprinted in the Gazette médicale [57]. English
translations appeared soon after in the American Journal of
the Medical Sciences [58] and in The Western Journal of the
Medical and Physical Sciences [59]; these translations rep-
resent the first uses of the term ‘neuromyelitis’ (N.B.: not
‘neuromyelitis optica’!) we could trace in the English-
language literature. Before Piorry, François Gabriel Boisseau
(1791–1836) had made the distinction in nomenclature be-
tween ‘névrilemmite’ and ’névromyélite’ already in 1830 in
his Nosographie organique [60], which we believe is the first
French account: ‘Quand le névrilème seul est enflammé
(névrilemmite), (. . .) Quand la substance médullaire du nerf
est elle-même enflammée (névromyélite)’ (see also Pierre Jo-
seph Mongellat, Monographie des irritations intermittentes,
Bruxelles, 1839: ‘isoler l’inflammation du nerf (névrite), de
celle du névrilème (névrilémite ou névrilite), et de celle en-
core de la pulpe nerveuse (névromyélite)’, with reference to
Boisseau).
An anonymous review of Hildenbrand’s Institutiones in
the Medicinisches Jahrbuch des kaiserlichen königlichen
Österreichischen Staates for 1837 (‘Entzündung (. . .) der
Nervenhäute, nevrolemitis, nevrymenitis, der Nervensub-
stanz nevromyelitis, gangliitis’) is the first account in the
German-language literature [61].
Hildenbrand, who coined the term ‘neuromyelitis’, may
still be known to some as the eponym of Hildenbrand’s dis-
ease, that is typhus (see the back references to ICD-9-CM
081.9). Coincidentally, of all diseases it was Hildenbrand’s
disease from which Peppo Acchioté, originator of the term
‘Devic’s disease’, was to die in 1916 [23].
One might accuse us of having overlooked that Piorry re-
ferred to Johann Christian Reil (1759–1813) when critici-
zing the above-mentioned distinction, not to Hildenbrand.
Reil, physician to Goethe and appreciated by many as the
father of modern psychiatry, was among the first to point
to the possibility of inflammation of the nerves by the dem-
onstration of vasa nervorum in his seminal Exercitationum
Anatomicarum Fasciculus Primus / De Structura Nervo-
rum, Halle, 1796. Reil also provided a very detailed descrip-
tion of the anatomy of the nerve and its sheaths. In the
fourth volume of his main work Ueber die Erkenntniß und
Kur der Fieber, Vienna, 1802, which is dedicated to feverish
nervous diseases, he indeed distinguished afflictions of the
Neurilem from those of the nervous Mark. However, Pior-
ry’s comment leads us astray. A meticulous search of both
Reil’s German and Latin writings failed to locate a single
mention of the term in question. It is therefore likely that
Piorry, when referring to Reil’s concept, used the termino-
logy of his own time. - Like Acchioté, Reil too died from
Hildenbrand’s disease.
Thomas Clifford Allbutt
Thomas Clifford Allbutt (1836–1925) is still known to
many as the inventor of the clinical thermometer and to
neurologists and ophthalmologists as the main instigator
(alongside Gowers) of the clinical use of the ophthalmo-
scope. In his famous lecture On the Ophthalmoscopic
Signs of Spinal Disease [62], Allbutt very briefly men-
tioned a patient with acute myelitis and ‘a sympathetic
eye disorder’. This case was long considered the first
account of a patient with NMO in the literature. We
recently re-discovered a more detailed description of
that patient tucked away in the appendix of Allbutt’s
textbook on the use of the ophthalmoscope [17,63].
While Allbutt might not have been the first to report on
a case of NMO (see above and reference [17]), it was
certainly his report that created the sustained interest of
neurologists and ophthalmologists in this rare syndrome.
Often, the palimpsestic syndrome mentioned above is
caused by what has been called the Matthew effect: ‘unto
every one that hath shall be given’ (Matthew 25:29, King
James Version). The incorrect (as we know today)
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attribution of primacy in relating a case of NMO to Allbutt
in so many articles in the field might - given that author’s
exceptional reputation and social status (the list of titles
held by Allbutt included K.C.B., M.A., M.D., LL.D., D.Sc., F.
R.C.P., F.R.S., F.L.S., F.S.A. and Regius Professor of Physic
at the University of Cambridge) - indeed represent a true
example of that effect. ‘Devic’s disease’, by contrast, is the
exception that proves the rule: While Devic became an ep-
onym, pioneers of modern neurology or ophthalmology
who were probably better known than Devic at that
time and had published on NMO before [11,14], such as
Clarke, Allbutt, Erb, or Knapp, came out empty-handed
in this case.
Allbutt never used the term ‘neuromyelitis optica’. As a
curious coincidence, however, of all authors Allbutt might
have been the first to use the term ‘neuromyelitis’ in a me-
dical text in a way distinct from Hildenbrand’s definition.
He did so in an address entitled On the Surgical Aids to
Medicine delivered at the inaugural meeting of the Midland
Medical Society on 19th October 1881 [64], in which he
referred to the discussion on surgical ‘nerve stretching’ that
had taken place at the International Medical Congress in
August the same year (for the rationale of that unusual pro-
cedure see Allbutt’s System of Medicine (1901): ‘When all
else fails, nerve stretching or even excision of a portion of
the nerve must be tried. The amount of tension brought to
bear on the nerve should be sufficient at least to lift the
limb off the table. One advantage is the breaking down of
adhesions, which in a small percentage of cases may have
something to do with the pain; but the main advantage
is counter-irritation very directly applied.’; cf. also John
Marshall, Neurectasy, or, Nerve-stretching for the relief or
cure of pain: being the Bradshaw Lecture delivered at the
Royal College of Surgeons on the 6th of December 1883, with
an appendix, Smith, Elder, and Co, London, 1887). In that
address Allbutt concluded that ‘nerve stretching (. . .) is the
only remedy which offers much hope of relief to sufferers
from the pains of chronic neuro-myelitis’. Although Allbutt
did not provide an exact definition, he explicitly referred to
patients with pain and ‘spinal disease’ [italics ours].
‘Ascending neuromyelitis’
For the sake of completeness, it should not go unmen-
tioned that the term ‘neuromyelitis’ was used by some
authors to refer to Landry’s paralysis, and the World Health
Organization’s International Classification of Diseases still
lists the term ‘ascending neuromyelitis’ among the syno-
nyms of ‘Guillain-Barre syndrome’ (ICD 61.0). A very rare
variant is ‘neuromyelitis hyperalbumenotica’ [65].
‘NMO’ in the 20th century: the same term, but evolving
concepts
The past 120 years have seen many different criteria for
the diagnosis of NMO, and, consequently, the exact
meaning (and, in particular, the extension) of the term
‘NMO’ has changed over the years. Some criteria
excluded (unnecessarily, as we know today) patients with
a relapsing course [66-68], a long interval between the
two index events myelitis and neuritis [66-68], only mild
para- or tetraparesis [69], incomplete myelitis [69], or
unilateral optic neuritis [66-68]. Although Devic and
Gault had already pointed to the fact that some patients
may develop symptomatic brainstem lesions, some cri-
teria also excluded patients with symptoms other than
optic neuritis and myelitis [2,66,70,71] (more recent
studies have proven Devic and Gault right [1,9]). Others
proposed excluding patients with co-existing systemic
lupus erythematosus (SLE) or Sjögren’s syndrome (SS)
[70]. However, AQP4-Ab-positive NMO was recently
shown to be frequently associated with other auto-
immune disorders, in particular SLE and SS [1,72-77].
Finally, some criteria considered spinal cord lesions
extending over more than two vertebral segments (as
measured by MRI) to be a prerequisite for a diagnosis of
NMO [70]. However, recent studies showed that short
lesions occasionally occur [1,78]. Similarly, brain lesions
on MRI were considered atypical for NMO in the past;
later studies, however, demonstrated that (mostly asymp-
tomatic) brain lesions indeed occur in around 60% of
patients with NMO, are sometimes present already at
onset, and may occasionally even meet MRI criteria for
MS [1,79,80].
NMO and MS: a difficult relationship
The question of the exact relationship between NMO
and classical multiple sclerosis (MS) has engaged neurol-
ogists for more than a century. While Devic and Gault
believed that, ‘des raisons suffisantes pour empêcher
d’admettre qu’à aucun moment des lésions aient pu
jamais prendre l’apparence anatomique de la sclérose en
plaques’ [7], others considered NMO a subtype of MS.
For example, Russell Brain, in his famous 1930 review
on MS and NMO, concluded that ‘the clinical and
pathological differences between neuromyelitis optica
and disseminated sclerosis appear to be differences of
acuteness and intensity only (. . .) there seems no justifi-
cation for separating them’ [81]. Only the discovery of
pathogenic antibodies to aquaporin-4 in a subset of
patients with NMO but not MS and the demonstration
of corresponding pathological differences [4,82-87] has
led to the recognition of ‘NMO-IgG-positive NMO’ as
an immunopathologically defined disease entity in its
own right distinct from classical MS.
All those restrictions in the definition of what the term
‘NMO’ should signify discussed above rested on the need
to differentiate NMO and MS solely on the basis of cli-
nical and radiological findings. With the availability of
AQP4-IgG, it became possible to distinguish the two
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conditions on the basis of laboratory findings. This
resulted in a change of perspective, which for the first
time permitted appreciation of the partial overlap be-
tween NMO and MS in terms of clinicoradiological
presentation and, in consequence, broadened substan-
tially the meaning attached to the term ‘NMO’.
While clinical and radiological features remain highly
relevant when it comes to distinguishing seronegative
NMO from MS (unless a specific laboratory marker for
either of these two conditions is found), the broadening
spectrum of syndromes reported associated with AQP4-
IgG renders it likely that future diagnostic criteria for
seropositive NMO will put less emphasis on clinicoradio-
logical findings but rather on strict laboratory standards
(this could include the requirement to confirm test results
in a second – and, if discrepant, a third –, methodologically
independent immunoassay with high specificity and
sensitivity as already recommended in current guide-
lines for other autoantibody mediated diseases of the
CNS).
NMO: disease or syndrome?
The recent progress in our understanding of the patho-
genesis of NMO brought about by the breakthrough dis-
covery of AQP4-Ab has challenged the traditional usage
of the term ‘NMO’.
Neglecting the large number of reports on cases of
possible rheumatic, (para)infectious, paraneoplastic,
metabolic, or toxic aetiology, some of which even date
back to the time of Devic and Gault, NMO was for a
long time treated by many as a disease entity rather than
a syndrome, as reflected by the widely applied term
‘Devic’s disease’ (or ‘Morbus Devic’, a variant used
mainly, but not exclusively, in the German-language
medical literature).
However, the lack of AQP4-IgG-seropositivity in a sub-
set of patients even in the most up-to-date, recombinant
assays, and in particular the demonstration of such a lack
in some patients with NMO and conditions that may
cause myelitis and optic neuritis by other mechanisms,
e.g. connective tissue disorders [72], paraneoplastic dis-
orders [88,89], or infectious diseases [90], has provided
strong evidence in favour of the hypothesis of NMO being
aetiopathogenetically heterogeneous. Importantly, some of
these assays have been shown to be capable of detecting
AQP4-Ab even in samples taken during remission and
under treatment with strong immunosuppressants such as
rituximab, azathioprine, mitoxantrone, or cyclophospha-
mide, practically ruling out the possibility that seronega-
tivity is generally the result of insufficient assay sensitivity
[1,91-93]). The notion of aetiopathological heterogeneity
is further supported by the recent demonstration of sig-
nificant clinical and paraclinical differences between sero-
positive and seronegative patients [1] and the finding of
antibodies to myelin oligodendrocyte glycoprotein in some
AQP4-Ab-negative patients [94-96].
Nonetheless, the current diagnostic criteria still subsume
AQP4-IgG-seropositive and –AQP4-IgG-seronegative cases
under the same disease heading, i.e. ‘NMO’ [78]. Employing
common criteria and a common designation for seroposi-
tive and seronegative NMO may be useful when it comes
to differentiating NMO from MS (the lack of oligoclonal
bands in most patients with seronegative NMO indicates
that the latter is not simply a clinicoradiological subtype of
MS but is of distinct pathogenesis [1]); however, this might
be problematic when it comes to treating patients with
NMO: While the demonstration of a pathogenic effect of
AQP4-IgG provides a strong rationale for B cell- and
antibody-targeted treatments in AQP4-IgG-seropositive
NMO [97,98], so far there is less strong evidence of a role
for B cells and pathogenic autoantibodies in the majority of
patients with seronegative NMO.
Based on the current concept of NMO being aetio-
logically heterogeneous (and unless this concept is formally
disproved, which is unlikely to happen), the term ‘Devic’s
disease’ should be avoided and replaced by ‘Devic’s syn-
drome’. Accordingly, we believe that the term ‘NMO’
should no longer be used as a disease designation; instead,
it should be used exclusively to refer to a clinical phenotype
or syndrome (characterized by optic neuritis and myelitis).
‘NMO spectrum disorder(s)’
Another problem attached to the current nomenclature
results from the recent finding that the spectrum of clin-
ical manifestations of AQP4 autoimmunity is wider than
previously thought and includes (1) various forms of
brainstem encephalitis in adults; (2) a broad variety of
cerebral symptoms in children; and (3) abortive forms
such as isolated longitudinally extensive transverse mye-
litis or isolated optic neuritis, which in NMO-IgG-
positive patients often convert to NMO [1,9,92,99-104].
Some authors proposed tackling this problem by intro-
ducing the term ‘NMO spectrum disorder’ (‘NMO-SD’),
a designation which was intended to be used to refer to
all major clinical manifestations that had by then been
reported in association with NMO-IgG.
Unfortunately, however, this potentially useful concept
[103] has been employed inconsistently in the literature:
1) Some authors use ‘NMO-SD’ as an abbreviation for
‘NMO spectrum disorder’ (note that ‘disorder’ is
used in the singular here) and thereby refer to a
shared underlying pathogenesis; by contrast, others
defined ‘NMO-SD’ as ‘NMO spectrum disorders’
(note the plural) and thereby refer to a spectrum of
clinico-radiological manifestations
2) Among those who understand ‘NMO-SD’ as a
spectrum of clinico-radiological manifestations, some
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include NMO, while others explicitly use the term
‘NMO-SD’ exclusively to refer to manifestations
other than NMO
3) Finally, some authors refer only to NMO-IgG-
positive cases, while others apply the term both to
NMO-IgG-positive and to NMO-IgG-negative cases
A more stringent use of the term ‘NMO-SD’ would be
desirable in order to make it easier to compare results
between studies. Moreover, it should be taken into ac-
count that while most patients with NMO-IgG-positive
myelitis, optic neuritis or brainstem encephalitis later
convert to NMO, most NMO-IgG-negative patients do
not [99,101,104]. Accordingly, labelling all such patients
with the term ‘NMO-SD’ is somewhat problematic.
‘Autoimmune AQP4 channelopathy’
As alternative designations, recently terms based on immu-
nopathology such as ‘autoimmune AQP4 channelopathy’ or
‘autoimmune AQP4 disease’ have been proposed [106-108].
We consider these suggestions useful. These terms could
be employed whenever reference is made to the common
pathogenenesis thought to underlie the AQP4-IgG-positive
cases. We would like to add the term ‘AQP4(−Ab-asso-
ciated) encephalomyelitis’ as another proposal. This term
would be in line with an already established nomenclature
that classifies cases of autoimmune encephal(omyel)itis
according to the patients’ autoantibody status (e.g. NMDAR
encephalitis, anti-Hu-associated encephalomyelitis); more-
over, including the word ‘encephalitis’ would take into ac-
count (1) that the brain is more often affected than
previously thought and (2) that the optic nerve is anatomi-
cally part of the encephalon.
Towards a descriptive and systematic nomenclature
However, for clinical purposes, as well as in the context
of clinical studies and treatment trials, neither a classifi-
cation solely based on common pathogenesis (“AQP4
channelopathy/encephalomyelitis”) nor the (ambiguous)
concept of NMO-SD seems completely sufficient; rather,
a more differentiated, descriptive and systematic classifi-
cation that reflects an individual patient’s exact clinical
phenotype, antibody status, and disease course might be
required, for the following reasons:
First, certain clinical features, laboratory findings, and/
or prognostic characteristics differ between AQP4-IgG-
positive and AQP4-IgG-negative patients [1,99,101,104,
109], among the various NMO-SD (as shown for time-
to-relapse, prognostic implications of clinical presenta-
tion at onset, and CSF findings [1,110]), and between
patients with monophasic disease and patients with re-
lapsing disease [1,2].
Second, treatment strategies might differ between AQP4-
IgG-positive and AQP4-IgG-negative patients (taking into
account possible differences in aetiology and pathogen-
esis), even among NMO-SD (e.g. based on differences as
to time-to-relapse and short-term prognosis [1]), and
between patients with monophasic and patients with
relapsing NMO-SD (which could well be manifestations
of different diseases, e.g. postinfectious ADEM vs. AQP4
autoimmunity).
Third, recommendations on diagnostic AQP4-IgG test-
ing may differ between patients with monophasic and
patients with relapsing disease as well as between the vari-
ous NMO-SDs: given the low frequency of AQP4-IgG in
patients with a first attack of isolated optic neuritis [97,98]
or atypical, isolated brainstem manifestations on the one
hand and the limited specificity of some of the currently
available immunoassays on the other hand, general screen-
ing for AQP4-IgG in all NMO-SD patients entails the risk
of an unfavourably high ratio of false-positive to true-
positive results and may therefore not be advisable.
Such descriptive nomenclature would distinguish between
AQP4-Ab-positive NMO and AQP4-Ab-negative NMO,
AQP4-Ab-positive and AQP4-Ab-negative (longitudinally
extensive) myelitis, AQP4-Ab-positive and AQP4-Ab-
negative optic neuritis, AQP4-Ab-positive and AQP4-Ab-
negative brainstem encephalitis, etc. In addition, the dis-
ease course (monophasic/first attack, relapsing) should be
specified and information should be provided regarding
co-existing autoimmunity as well as regarding the sus-
pected aetiology in seronegative patients.
Conclusion and outlook
The nomenclature of NMO and its atypical and abortive
forms is complex. Its meandering evolution and this
complexity reflect the ongoing endeavours by genera-
tions of neurologists to facilitate distinction of this rare
condition from MS and other related conditions, all the
while making room for improvements in diagnosis and
in our understanding of the pathogenesis of NMO.
Clear classifications are not a pure academic exercise
but a crucial prerequisite for future treatment trials. Our
paper aims to fuel the ongoing discussion about the
need for new diagnostic criteria for NMO and revisions
in nomenclature. We hope that the proposals set out
herein will help to solve some of the issues attached to
the current nomenclature.
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